ASTCT Supports the FDA’s Accelerated Approval of AMTAGVI for Treatment of Metastatic Melanoma
The American Society for Transplantation and Cellular Therapy® (ASTCT®) supports the decision by the US Food and Drug Administration’s (FDA) to grant accelerated approval to...
AIM at Melanoma Celebrating 20 Year Anniversary
Twenty years ago, the AIM at Melanoma Foundation was established by a determined woman with a relentless drive to find the cure for melanoma while...
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection versus KEYTRUDA
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with...